首页> 外文期刊>Peritoneal dialysis international: Journal of the International Society for Peritoneal Dialysis >Pathogenesis and treatment of encapsulating peritoneal sclerosis: basic and translational research.
【24h】

Pathogenesis and treatment of encapsulating peritoneal sclerosis: basic and translational research.

机译:封装性腹膜硬化的发病机理和治疗:基础研究和转化研究。

获取原文
获取原文并翻译 | 示例
           

摘要

Encapsulating peritoneal sclerosis is a devastating condition in long-term peritoneal dialysis patients. Animal models have employed chemical insults to simulate its pathology and have provided insights into its pathophysiology, which appears to include inflammation, angiogenesis, and fibrosis. Monitoring of biomarkers and interruption of molecular pathways have provided potential interventions to slow or prevent the disease process. However, there remain many questions concerning the trigger that alters chronic peritoneal inflammation in peritoneal dialysis to severe sclerosis, peritoneal adhesions, and bowel obstruction. Further advances in therapy will likely require an effective means of an early diagnosis through related biomarkers, which in turn will require further advances in the understanding of the pathogenesis of this disease process.
机译:在长期腹膜透析患者中​​,封装腹膜硬化症是毁灭性的情况。动物模型已经采用化学侮辱来模拟其病理学,并提供了对其病理生理学的见解,其中似乎包括炎症,血管生成和纤维化。生物标志物的监测和分子途径的中断为减缓或预防疾病进程提供了潜在的干预措施。然而,关于引发改变腹膜透析中慢性腹膜炎症至严重硬化,腹膜粘连和肠梗阻的诱因仍然存在许多问题。进一步的治疗进展可能需要通过相关生物标记物进行早期诊断的有效手段,而这反过来又需要对这种疾病过程的发病机理的进一步了解。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号